Habitual Diet and Avocado Trial (HAT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Loma Linda, California, United States, 92354
- Loma Linda University
-
Los Angeles, California, United States, 90095
- University of California Los Angles (UCLA)
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts University
-
-
Pennsylvania
-
University Park, Pennsylvania, United States, 16802
- Pennysylvania State University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Increased waist circumference defined as ≥35 inches for women, ≥40 inches for men
- At least 25 years old at screening
- Not currently eating more than 2 avocados per month (habitual intake in U.S.)
Exclusion Criteria:
- Does not eat avocados
- Sensitive / allergic to avocados
- Allergies to latex or oral allergy syndrome
- Not willing or unable to undergo MRI scans
- Unstable medical condition such as on dialysis for renal disease, cardiac, gastrointestinal, or hepatic disease, cancer (non-melanoma skin cancer >5 years ago acceptable, any cancer site >10yrs without recurrence).
- Pregnant, lactating, intention of pregnancy
- Lost or gained 10 lbs of body weight in last year
- Following restricted or weight loss dietary patterns
- Unstable anti-anxiety / anti-depressive / anti-psychotic medication use defined as dose change within last 6 months
- Oral steroid use within the last 6 months longer than 7 days
- Elevated alcohol intake (7+ drinks/week females; 14+ drinks/week males)
- Participation in another clinical intervention trial within 30 days of baseline
- PI judgment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention Daily Avocado
Participants will follow their usual diet and lifestyle but also be provided with 1 avocado to consume per day for 6 months.
To maximize compliance, participants will be provided with resources on how to choose, store and ripen avocados along with simple usage ideas.
Specific nutrition guidance will not be provided.
Participants will pick up fresh avocados every 2 weeks with minimal interaction with study personnel.
Compliance visits will be conducted monthly.
|
Participants follow their usual diet and lifestyle but also are provided with 1 avocado to consume per day for 6 months.
|
|
No Intervention: Control Usual Diet and Lifestyle
Participants will be instructed to follow their usual diet and lifestyle.
Participants will be allowed to consume up to 2 avocados per month, but avocado consumption will not be encouraged and no avocados will be provided.
Compliance visits will be conducted monthly.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visceral adiposity
Time Frame: Visit 1 (Screening, -2 to 0 weeks) and Visit 8 (26 weeks)
|
Non-contrast MRI scans will be performed to assess the volume of visceral adipose tissue.
The outcome will be pre-post difference, compare the estimated mean change from baseline to follow-up in the 2 randomized groups with all tests of group differences performed according to the intent to treat.
|
Visit 1 (Screening, -2 to 0 weeks) and Visit 8 (26 weeks)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hepatic lipid content
Time Frame: Visit 1 (Screening, -2 to 0 weeks and Visit 8 (26 weeks)
|
Non-contrast MRI scans will be performed to assess hepatic lipid content/hepatic fat fraction.
|
Visit 1 (Screening, -2 to 0 weeks and Visit 8 (26 weeks)
|
|
Metabolic syndrome markers (serum triglycerides, serum cholesterol, fasting serum glucose, fasting insulin)
Time Frame: Visit 2 (Baseline visit 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks)
|
Phlebotomy is performed after a minimum 8 hour fast.
Specimens will be separated and aliquoted, and shipped for analysis to Tufts University site for: fasting total cholesterol, triglyceride, high density lipo-protein cholesterol (HDL-C), glucose and insulin.
LDL will be calculated using the Friedewald equation unless fasting triglyceride levels are > 400 mg/dL in which case they will be measured using a direct LDL assay.
There will be a comparison of the estimated mean change from baseline to follow-up with all tests of group differences performed according to intent to treat.
|
Visit 2 (Baseline visit 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks)
|
|
High-sensitivity C-reactive protein (hs-CRP)
Time Frame: Visit 2 (baseline/randomization, Week 0), Visit 5 (12 weeks), Visit 8 (26 weeks)
|
C-reactive protein (CRP) is a protein that the liver makes when there is inflammation in the body.
Also called a marker of inflammation and can be measured with the hs-CRP test.
Inflamed arteries puts individuals at greater risk of heart disease, heart attack, stroke and peripheral arterial disease.
A fasting sample will be obtained, shipped to and analyzed at Tufts University for hsCRP.
|
Visit 2 (baseline/randomization, Week 0), Visit 5 (12 weeks), Visit 8 (26 weeks)
|
|
Red blood cell (RBC) monounsaturated fat/polyunsaturated fat (MUFA/PUFA) ratio
Time Frame: Visit 2 (Baseline/Randomization Visit, 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks)
|
Fasting RBC specimens shipped to Tufts University for analysis of RBC fatty acid profiles.
The Fatty Acid Profile measures major fatty acids found in red blood cells.
|
Visit 2 (Baseline/Randomization Visit, 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks)
|
|
Blood pressure
Time Frame: Visit 2 (baseline/randomization 0 weeks) Visit 3 (4 weeks), Visit 4 (8 weeks), Visit 5 (12 weeks), Visit 6 (16 weeks), Visit 7 (10 weeks), Visit 8 (26 weeks)
|
Seated blood pressure will be measured at each visit (except the screening visit) utilizing automated devices as per a standardized protocol across all sites.
Three measurements will be taken after a 5 minute rest period, 1 minute apart.
The last two readings are averaged for analysis.
|
Visit 2 (baseline/randomization 0 weeks) Visit 3 (4 weeks), Visit 4 (8 weeks), Visit 5 (12 weeks), Visit 6 (16 weeks), Visit 7 (10 weeks), Visit 8 (26 weeks)
|
|
Weight
Time Frame: Visit 2 (baseline/randomization), Visit 5 (12 weeks) and Visit 8 (26 weeks-final)
|
Participants will be weighed at all in-study visits using high quality digital scales commonly used in clinical practice and that are in good working order.
Participants will be weighed in light street clothes without shoes.
The same scale is used throughout the trial.
|
Visit 2 (baseline/randomization), Visit 5 (12 weeks) and Visit 8 (26 weeks-final)
|
|
Waist circumference
Time Frame: Visit 1 (screening -2 to 0 weeks), Visit 2 (baseline/randomization 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks)
|
A measuring tape specifically designed for waist circumference (recommended brands include Gulick or Seca) will be used according to a standardized procedure outlined in the trial Manual of Procedures.
Waist circumference will be used during screening to assess eligibility.
Measurements will be taken against the skin at the approximate midpoint between the lower margin of the last palpable rib and the top of the iliac crest.
Two measurements are obtained at each visit and averaged.
|
Visit 1 (screening -2 to 0 weeks), Visit 2 (baseline/randomization 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks)
|
|
Diet, Food and Avocado Satisfaction
Time Frame: Visit 2 (baseline/randomization, 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks)
|
Questions regarding participant satisfaction with the diet and food intervention will be assessed by completing the Diet, Food and Avocado Satisfaction Questionnaire.
The questionnaire will only be completed by participants randomized to consume one avocado a day.
The questionnaire is completed within 24 hours of a clinic visit and can be self- or staff administered.
It consists of 14 questions about eating and preparing avocados each having a 100 point Likert scale with responses of "Not at all" and "Extremely".
|
Visit 2 (baseline/randomization, 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks)
|
|
Quality of life RAND 36-Item Short Form Survey Instrument (SF-36)
Time Frame: Visit 2 (baseline), Visit 5 (12 weeks) and Visit 8 (26 weeks-final)
|
All participants will complete the RAND (research and development) 36-Item Health Survey to assess 8 health concepts: physical functioning, bodily pain, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue and general health perceptions.All items are scored so that a high score defines more favorable health state.
Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100.
Items in the same scale are averaged together to create 8 scale scores.
Items that are left blank are not taken into account when calculating scale scores.
|
Visit 2 (baseline), Visit 5 (12 weeks) and Visit 8 (26 weeks-final)
|
|
Quality of Life RAND 20-Item Short Form Survey (SF-20)
Time Frame: Visit 3 (4 weeks), Vist 4 (8 weeks) Visit 6 (16 weeks), Visit 7 (20 weeks)
|
The 20-item Short Form Health Survey (SF-20) was designed to reduce respondent burden while achieving minimum standards of precision for purposes of group comparisons involving multiple health dimensions.
It includes 7 items to assess physical functioning, 2 items on role functioning, 1 social functioning survey item, 5 items to assess mental health, 4 items on current health perceptions and 1 item on pain.
Participants in the control group will complete the RAND 20-Item Short Form Survey.
|
Visit 3 (4 weeks), Vist 4 (8 weeks) Visit 6 (16 weeks), Visit 7 (20 weeks)
|
|
Sleep quality
Time Frame: Visit 2 (baseline), Visit 5 (12 weeks) and Visit 8 (26 weeks-final)
|
All participants will complete the Pittsburgh Sleep Quality Index questionnaire (PSQI) which is a self-rated questionnaire that assesses sleep quality and disturbances over a 1-month time time interval.
19 individual items generate seven "component" scores: subjective sleep quality; sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication and daytime dysfunction.
The sum of scores for the 7 components yield one global score.
|
Visit 2 (baseline), Visit 5 (12 weeks) and Visit 8 (26 weeks-final)
|
|
24-hour diet recall
Time Frame: Visit 1 (screening, -2 to 0 weeks), Visit 4 (8 weeks), visit 6 (16 weeks), Visit 8 (26 weeks)
|
Four 24-hour dietary recalls will be conducted for each study participant during the course of the study.
The goal for the 3 intra-study recalls is to capture intake data for 2 weekdays and 1 weekend day for each participant.
The recalls are collected and analyzed using Nutrition Data System for Research (NDSR) software Vs 2017.
The Loma Linda University site and Tufts University will be responsible for collecting 50% each of the 24 hour recalls across all study sites.
They will follow a standardized manual of procedures for dietary data collection and dietary data management.
Outcome data from NDSR will include daily estimated energy and nutrient intake, as well as food, food group and dietary supplement data.
|
Visit 1 (screening, -2 to 0 weeks), Visit 4 (8 weeks), visit 6 (16 weeks), Visit 8 (26 weeks)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: David Reboussin, PhD, Wake Forest University Health Sciences
Publications and helpful links
General Publications
- Berryman CE, West SG, Fleming JA, Bordi PL, Kris-Etherton PM. Effects of daily almond consumption on cardiometabolic risk and abdominal adiposity in healthy adults with elevated LDL-cholesterol: a randomized controlled trial. J Am Heart Assoc. 2015 Jan 5;4(1):e000993. doi: 10.1161/JAHA.114.000993.
- Bertoli S, Leone A, Vignati L, Bedogni G, Martinez-Gonzalez MA, Bes-Rastrollo M, Spadafranca A, Vanzulli A, Battezzati A. Adherence to the Mediterranean diet is inversely associated with visceral abdominal tissue in Caucasian subjects. Clin Nutr. 2015 Dec;34(6):1266-72. doi: 10.1016/j.clnu.2015.10.003. Epub 2015 Oct 20.
- Cespedes Feliciano EM, Tinker L, Manson JE, Allison M, Rohan T, Zaslavsky O, Waring ME, Asao K, Garcia L, Rosal M, Neuhouser ML. Change in Dietary Patterns and Change in Waist Circumference and DXA Trunk Fat Among Postmenopausal Women. Obesity (Silver Spring). 2016 Oct;24(10):2176-84. doi: 10.1002/oby.21589. Epub 2016 Aug 22.
- Dhillon J, Tan SY, Mattes RD. Almond Consumption during Energy Restriction Lowers Truncal Fat and Blood Pressure in Compliant Overweight or Obese Adults. J Nutr. 2016 Dec;146(12):2513-2519. doi: 10.3945/jn.116.238444. Epub 2016 Nov 2.
- Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Covas MI, Fiol M, Gomez-Gracia E, Lopez-Sabater MC, Vinyoles E, Aros F, Conde M, Lahoz C, Lapetra J, Saez G, Ros E; PREDIMED Study Investigators. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med. 2006 Jul 4;145(1):1-11. doi: 10.7326/0003-4819-145-1-200607040-00004. Erratum In: Ann Intern Med. 2018 Aug 21;169(4):270-271.
- Gower BA, Goss AM. A lower-carbohydrate, higher-fat diet reduces abdominal and intermuscular fat and increases insulin sensitivity in adults at risk of type 2 diabetes. J Nutr. 2015 Jan;145(1):177S-83S. doi: 10.3945/jn.114.195065. Epub 2014 Dec 3.
- Paniagua JA, Gallego de la Sacristana A, Romero I, Vidal-Puig A, Latre JM, Sanchez E, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care. 2007 Jul;30(7):1717-23. doi: 10.2337/dc06-2220. Epub 2007 Mar 23.
- Ross R, Rissanen J, Pedwell H, Clifford J, Shragge P. Influence of diet and exercise on skeletal muscle and visceral adipose tissue in men. J Appl Physiol (1985). 1996 Dec;81(6):2445-55. doi: 10.1152/jappl.1996.81.6.2445.
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421. No abstract available.
- Wien M, Haddad E, Oda K, Sabate J. A randomized 3x3 crossover study to evaluate the effect of Hass avocado intake on post-ingestive satiety, glucose and insulin levels, and subsequent energy intake in overweight adults. Nutr J. 2013 Nov 27;12:155. doi: 10.1186/1475-2891-12-155.
- O'Neil, et al. Avocado consumption by adults is associated with better nutrient intake, diet quality and some measures of adiposity: NHANES Survey, 2001-2012. Int Med Rev In press.
- Lichtenstein AH, Kris-Etherton PM, Petersen KS, Matthan NR, Barnes S, Vitolins MZ, Li Z, Sabate J, Rajaram S, Chowdhury S, Davis KM, Galluccio J, Gilhooly CH, Legro RS, Li J, Lovato L, Perdue LH, Petty G, Rasmussen AM, Segovia-Siapco G, Sirirat R, Sun A, Reboussin DM. Effect of Incorporating 1 Avocado Per Day Versus Habitual Diet on Visceral Adiposity: A Randomized Trial. J Am Heart Assoc. 2022 Jul 19;11(14):e025657. doi: 10.1161/JAHA.122.025657. Epub 2022 Jul 5.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Genetic Diseases, Inborn
- Insulin Resistance
- Hyperinsulinism
- Metabolism, Inborn Errors
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Lipid Metabolism, Inborn Errors
- Hyperglycemia
- Cardiovascular Diseases
- Metabolic Syndrome
- Hypercholesterolemia
- Hypoalphalipoproteinemias
- Hypolipoproteinemias
Other Study ID Numbers
Other Study ID Numbers
- IRB00047011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.